Maggie L. Shaw

On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.

On Friday, President-elect Donald Trump announced his nominations to lead the CDC, for FDA Commissioner, and for Surgeon General.

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight loss, with their safety and efficacy primary outcomes of interest.

In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.

Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.

Coverage from the IVBM event with Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).

Coverage from the IVBM Regional event in Boston, Massachusetts.

This approval is the fifth overall for bimekizumab (Bimzelx; UCB Pharma) in the US, and they all have come in the last 13 months.

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

Lung cancer is the top cause of cancer-related death worldwide.

Investigators were seeking a greater understanding of risk factors for hidradenitis suppurativa, a chronic inflammatory skin disease, concentrating on how it presents in skin of color.

At our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Brita Roy, MD, MPH, MHS, spoke on improving cancer health outcomes through community-clinical partnerships.

In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk stratifying patients.

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

Two doses of vitamin D were investigated for their potential to have a positive impact on systolic and diastolic blood pressures when administered in conjunction with calcium.

This research is not the first to uncover duplicative and wasteful spending on health care for veterans who receive care primarily through the Veterans Health Administration as they are also enrolled in Medicare Advantage plans.

In this study, investigators were seeking to uncover potential genetic correlations between hidradenitis suppurativa and downstream risk of cardiometabolic disease, such as coronary artery disease (CAD) and diabetes, in older adults.

As part of our coverage of the biennial AIDS conference from the International AIDS Society, we spoke with Madalitso Juwayeyi, program manager at FACT-Malawi, to learn more about her organization and how it strives to serve the sexual and reproductive health needs of adolescent girls and young women in her native Malawi.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease progression following standard-of-care therapies that include immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.

The American Journal of Managed Care® and Vanderbilt University Medical Center partnered on a recent Institute for Value-Based Medicine® event, which had the theme, “Bringing the Future to the Present in Cancer Care.”

Financial toxicity is a burden many patients and their families unfortunately are forced to shoulder, leading some to delay or skip care and incur bills related to their care that they lack the financial capacity to pay off.

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions.

More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery.

UCB submitted a supplemental biologics license application for bimekuzimab (Bimzelyx) to the FDA in April for the drug’s approval in moderate to severe hidradenitis suppurativa (HS).

Patients with Medicare coverage and whose incomes fall between 100% and 400% or less of the federal poverty level may find themselves in a tricky financial situation concerning their ability to pay the Medicare Part A hospital deductible.

Prior authorizations (PA) have been the subject of much scrutiny as of late through research demonstrating subsequent limited access to care in the aftermath of PA denials from use of artificial intelligence (AI) technologies.